Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.

African Mother and newborn © Arne Hoel World Bank

Febrile illness is the most common reason for childhood healthcare visits globally, with hundreds of millions of cases of fever in 0 to four-year-olds presenting at health facilities every year. Historically, in malaria-endemic countries it was assumed that malaria was the cause of fever, but with the advent of rapid diagnostic tests (RDTs) for malaria, combined with intensified malaria control activities over the last decade, the incidence rate of malaria has been substantially reduced. Health workers and researchers have noted that once malaria is ruled out, it is difficult to diagnose febrile illness due to limited diagnostic tools, laboratory facilities and the scarcity of comprehensive surveillance networks in low-resource settings. Thus, patients with fever are often misdiagnosed and given inappropriate treatments, such as antibiotics in the absence of a confirmed diagnosis, which in addition to mistreating individual patients may contribute to antimicrobial resistance.

Today, the ongoing pandemic of COVID-19, a disease with a potential presentation of non-specific febrile illness, further highlights the need for accurate diagnostics, strong surveillance networks and standardized data to efficiently handle this disease alongside addressing the multitudes of causes of potentially co-existing non-malarial febrile illnesses.

In order to map the main causes of fever in all malaria-endemic regions, researchers associated with the WorldWide Antimalarial Resistance Network (WWARN); the Infectious Diseases Data Observatory (IDDO) at the University of Oxford, the Foundation for Innovative New Diagnostics (FIND), London School of Hygiene & Tropical Medicine (LSHTM), University of Otago, University of Hong Kong, Fundação Oswaldo Cruz (Fiocruz), and the MORU Tropical Health Network - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) and Cambodia-Oxford Medical Research Unit (COMRU) screened more than 100,000 articles published between 1980 and 2015 to provide the most comprehensive data available to date.

Read the full story on the IDDO website

Similar stories

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Registration is open for The Global Health Network Conference 2022

To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.

Gail Carson chair of GOARN

Dr Gail Carson from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is nominated chair of WHO Global Outbreak Alert & Response Network (GOARN)

Enhanced vaccination against Japanese encephalitis virus could reduce encephalitis prevalence by one third in SE Asia

Encephalitis is a worldwide public health issue, with a substantially high burden among children in Southeast Asia. A large study of the causes of childhood encephalitis in SE Asia suggests that enhanced and effective vaccination against the Japanese encephalitis virus alone could reduce encephalitis prevalence by one third.

RECOVERY trial celebrates two-year anniversary of life-saving dexamethasone result

Two years ago, the RECOVERY trial gave the world its first breakthrough against coronavirus: the discovery that an inexpensive steroid pill, dexamethasone, reduced deaths by up to a third from COVID-1. Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.